Testing hormone tests to predict response to magnetic brain stimulation in depression
Tests whether two hormone tests predict who responds to brain stimulation for major depression.
Plain-language title generated from the registry record
Registry title: Added Value of a Neuroendocrine Test Battery in the Response to Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment
Key facts
- Where
- Rouffach, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT05964192, who can take part
Where in France
- Centre Hospitalier RouffachRouffach, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Rouffach
- Trial code
- NCT05964192
- Record updated
- 14 February 2024
- Original description
The primary objective of the study is to determine the predictive value of the neuroendocrine tests TRH-∆∆TSH (thyreoliberin - thyreostimulin) and DST (dexamethasone suppression test) in the subsequent response to rTMS-TBS (repetitive transcranial magnetic stimulation-theta burst stimulation) treatment, defined as at least a 50% decrease in depression score after 20 sessions of rTMS-TBS.Read full original descriptionShow less
Added Value of a Neuroendocrine Test Battery in the Response to Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment : a Pilot Study in Major Depression (Endo-rTMS)
The primary objective of the study is to determine the predictive value of the neuroendocrine tests TRH-∆∆TSH (thyreoliberin - thyreostimulin) and DST (dexamethasone suppression test) in the subsequent response to rTMS-TBS (repetitive transcranial magnetic stimulation-theta burst stimulation) treatment, defined as at least a 50% decrease in depression score after 20 sessions of rTMS-TBS.
Inclusion: Patient with a characterized depressive episode defined according to DSM-5 (diagnostic and statistical manual of mental disorders) criteria; Patient between the ages of 18 and 65 years; Inpatient with an inadequate response to two prior well-conducted antidepressant treatments (Hamilton 17-item scale [HAMD-17] score at inclusion≥ 18) ; Patient with written informed consent to participate in the study; Patient enrolled in or receiving social security benefits.
Exclusion: Patient previously treated with monoamine oxidase inhibitor (MAOI) antidepressant or lithium salts (within 6 months prior to inclusion); Patient with a contraindication to neuroendocrine testing (hypersensitivity to the active substance or to one of the excipients); Patient with a contraindication to rTMS:; cochlear implant,; cardiac pacemaker,; metal clips, stents or other electronic implants within one meter of the stimulation coil,; intracranial hypertension,; poorly balanced comitiality,; in the case of well-balanced comitiality, a neurological consultation with electroencephalogram (EEG) is planned before including the patient; Patient with endocrinopathy ; Pregnant or lactating patient; Patient under court protection or deprived of liberty; Patient under guardianship/guardianship.